NEW YORK
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated clinical data at the Lancet Viral Hepatitis Conference in Shanghai, China from April 10-12, 2015. The data are from studies involving patients with chronic HBV infection who were treated with REP 2139-Ca in combination with immunotherapy and /or entecavir (ETV).
REP 2139-Ca used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV was safe and well-tolerated and resulted in an antiviral response that was profound and includes: the elimination (up to 7 log reduction to LLOQ) of HBsAg in the blood seroconversion for both HBsAg and HBeAg and, the elimination (up to 6 log reduction to LLOQ) of serum HBV DNA. These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies.
Replicor’s poster presentation will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For more information on the 2015 Lancet Viral Hepatitis Meeting: www.asianoncologysummit.com/vhep-summit.asp
About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.
CONTACT
Replicor
Alexandra Peterson, 212-508-9709
apeterson@makovsky.com
